Purple Biotech (PPBT) ehemals KTOV (Mkap $16 M) ( Cash $17 M) US Zulassungsantrag diesen Quartal (Seite 16)
eröffnet am 18.07.17 17:14:19 von
neuester Beitrag 31.03.24 12:32:14 von
neuester Beitrag 31.03.24 12:32:14 von
Beiträge: 1.796
ID: 1.257.452
ID: 1.257.452
Aufrufe heute: 0
Gesamt: 149.313
Gesamt: 149.313
Aktive User: 0
ISIN: US74638P1093 · WKN: A2QLTP · Symbol: 1YI1
0,4860
EUR
-3,76 %
-0,0190 EUR
Letzter Kurs 06.05.24 Tradegate
Neuigkeiten
25.04.24 · globenewswire  |
28.03.24 · globenewswire |
14.03.24 · globenewswire |
05.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6.300,00 | +4.940,00 | |
| 1,4600 | +34,94 | |
| 1,2300 | +24,24 | |
| 2,7600 | +20,00 | |
| 0,8000 | +19,40 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 21,600 | -20,00 | |
| 1,3800 | -20,80 | |
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 68.793.638 von Sven_Bonn am 16.07.21 08:37:41Hallo Sven. Danke, dass du uns weiter auf dem laufenden hälst.
konkret geht es um diesen ETF:
Fund Description and Objective
The ARK Israel Innovative Technology ETF (IZRL) seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the ARK Israeli Innovation Index, which is designed to track the price movements of exchange-listed Israeli companies whose main business operations are causing disruptive innovation in the areas of genomics, health care, biotechnology, industrials, manufacturing, the Internet or information technology.
The Index includes equity securities and depositary receipts of exchange listed companies that are incorporated and/or domiciled in Israel (‘‘Israeli Companies’’) and are included in one of the following economic sectors as defined by FactSet Research Systems: (i) health technology, (ii) communications, (iii) technology services, (iv) electronic technology, (v) consumer services, or (vi) producer manufacturing.
https://ark-funds.com/israel-etf
Fund Description and Objective
The ARK Israel Innovative Technology ETF (IZRL) seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the ARK Israeli Innovation Index, which is designed to track the price movements of exchange-listed Israeli companies whose main business operations are causing disruptive innovation in the areas of genomics, health care, biotechnology, industrials, manufacturing, the Internet or information technology.
The Index includes equity securities and depositary receipts of exchange listed companies that are incorporated and/or domiciled in Israel (‘‘Israeli Companies’’) and are included in one of the following economic sectors as defined by FactSet Research Systems: (i) health technology, (ii) communications, (iii) technology services, (iv) electronic technology, (v) consumer services, or (vi) producer manufacturing.
https://ark-funds.com/israel-etf
Hallo zusammen,
war ja die letzten Monate ziemlich still...
Das scheint genauso gewollt gewesen zu sein..
Schaut doch mal unter folgendem Link:
https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_ISRAEL_INNOVATIVE_TECHNOLOGY_ETF_IZRL_HOLDINGS.pdf" target="_blank" rel="nofollow ugc noopener">https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_ISRAEL_INNOVATIVE_TECHNOLOGY_ETF_IZRL_HOLDINGS.pdf
Still und heimlich hat https://ark-funds.com/ investiert..
Gestern Abend gab es EINEN Kauf in US von ca. 250.000 PPBT ADR...
Das wird kaum Retail gewewsen sein....
In Summe hält ark funds über 437.000 Aktien.. Tendenz weiter steigend.
Ark kommt aus Isreal und investiert in:
"ARK believes innovation is key to growth. We aim to capture long-term growth and capital appreciation created by disruptive innovation."
Wir werden sehen, was heute passiert... gestern sah es ja schon einmal sehr gut aus..
Wird ja auch Zeit.
LG
Sven
war ja die letzten Monate ziemlich still...
Das scheint genauso gewollt gewesen zu sein..
Schaut doch mal unter folgendem Link:
https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_ISRAEL_INNOVATIVE_TECHNOLOGY_ETF_IZRL_HOLDINGS.pdf" target="_blank" rel="nofollow ugc noopener">https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_ISRAEL_INNOVATIVE_TECHNOLOGY_ETF_IZRL_HOLDINGS.pdf
Still und heimlich hat https://ark-funds.com/ investiert..
Gestern Abend gab es EINEN Kauf in US von ca. 250.000 PPBT ADR...
Das wird kaum Retail gewewsen sein....
In Summe hält ark funds über 437.000 Aktien.. Tendenz weiter steigend.
Ark kommt aus Isreal und investiert in:
"ARK believes innovation is key to growth. We aim to capture long-term growth and capital appreciation created by disruptive innovation."
Wir werden sehen, was heute passiert... gestern sah es ja schon einmal sehr gut aus..
Wird ja auch Zeit.
LG
Sven
Guten Morgen zusammen,
da war ja gestern Einiges los nachbörslich...
Form 6K
https://newsfilter.io/a/02538af80b7e819abe8a2260b0172ec2
Sales Agreement
Purple Biotech Ltd. (the “Registrant” or the “Company”) is announcing that on June 9, 2021, the Company entered into an Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC (the “Agent”) to issue and sell the Company’s American Depositary Shares, each representing 10 ordinary shares of the Company no par value (the “ADSs”), with gross sales proceeds of up to $50.0 million, from time to time, through an at the market offering through the Agent.
Subject to the terms and conditions of the Sale Agreement, the Agent has agreed to use its commercially reasonable efforts, consistent with its normal sales and trading practices to place the ADSs with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in a written notice from the Company. The sales, if, under the Sale Agreement will be made (i) in negotiated transactions with the consent of the Company or (ii) by any other method permitted by law deemed to be an “at the market” offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”), including block transactions, sales made directly on The Nasdaq Capital Market or any other existing trading market of the ADSs. The Sale Agreement provides that the commission payable to the Agent for sales of ADSs with respect to which the Agent acts as sales agent shall be up to 4.0% of the gross proceeds of ADSs sold pursuant to the Sale Agreement.
The Sale Agreement contains customary representations and warranties of the parties to each other and indemnification and contribution provisions under which the Company and the Agent have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. The Agent and the Company have the right, by giving written notice as specified in the Sale Agreement, to terminate the Sale Agreement.
The offering has been registered under the Securities Act pursuant to the Company’s shelf registration statement on Form F-3 (Registration No. 333-235327), as supplemented by the prospectus supplement dated June 9, 2021 relating to the sale of the ADSs.
A copy of the Sale Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Sale Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.
A copy of the opinion of ABZ Law Office of Jerusalem, Israel relating to the validity of the ordinary shares underlying the ADSs to be issued in accordance with the Sale Agreement is filed herewith as Exhibit 5.1. A copy of the opinion of Haynes and Boone LLP relating to the validity of the ADSs is filed herewith as Exhibit 5.2
This report on Form 6-K, and the above referenced registration statement and prospectus supplement, shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of ADSs or ordinary shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
------
Sales Agreement Form 424B5 - filed by Purple Biotech Ltd.
https://newsfilter.io/a/4c7ceea147b08ad5a05a2c2e0271623f
Purple Biotech Ltd.
Up to $50,000,000
American Depositary Shares representing Ordinary Shares
We have entered into an open market sale agreementSM (the “sales agreement”), with Jefferies LLC (“Jefferies” or the “Agent”), relating to the sale of American Depositary Shares (“ADSs”), representing our ordinary shares offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell ADSs having an aggregate offering price of up to $50,000,000 from time to time through Jefferies, acting as our agent.
The ADSs are listed on the Nasdaq Capital Market (“NASDAQ”) under the symbol “PPBT.” On June 8, 2021, the last reported sale price of the ADSs on NASDAQ was $5.20 per ADS. Our ordinary shares are also listed on the Tel Aviv Stock Exchange (“TASE”) under the symbol “PPBT.” On June 8, 2021, the last reported sale price of our ordinary shares on the TASE was NIS 16.46, or $5.10 per ordinary share (based on the exchange rate reported by the Bank of Israel on such date, which was NIS 3.243= $1.00).
Sales of the ADSs, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Jefferies is not required to sell any specific amount of securities but will act as a sales agent using commercially reasonable efforts to sell on our behalf all of the ADSs requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between the Jefferies and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The compensation to the Jefferies for sales of ADSs sold pursuant to the sales agreement will be an amount up to 4.0% of the gross proceeds of any ADSs sold under the sales agreement. In connection with the sale of the ADSs on our behalf, Jefferies will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act or under the Exchange Act of 1934, as amended (the “Exchange Act”). See “Plan of Distribution” on page S-25 of this prospectus supplement for additional information concerning the Jefferies’ compensation.
Investing in our securities involves a high degree of risk. Please read “Risk Factors” beginning on page S-6 of this prospectus supplement, on page 3 of the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.
---------------
financials Results (3-month)
https://fintel.io/doc/sec-purple-biotech-ltd-1614744-6k-2021…
----
Wird interessant jetzt.. Nun können Sie Aktien im Gegenwert von 50 Mio. USD ausgeben, wann immer sie es wollen und der Markt es zulässt. Da sie aktuell kein Cash benötigen, scheint es aus meiner Sicht eher so, dass diese Aktien strategisch benutzt werden, um zum Beispiel einen Partner mit ins Boot zu holen..
Ähnlich hat es zum Beispiel auch Trillium mit Pfizer gemacht...
Auf jeden Fall ist es nun interessant zu sehen, was passiert. NAchbörslich hat es jedenfalls KEINEN Abverkauf gegeben, der Markt hat es eher positiv aufgenommen...
Bei PPBT ist halt immer alles möglich, KEINE langweilige Aktie :-)
LG
Sven
da war ja gestern Einiges los nachbörslich...
Form 6K
https://newsfilter.io/a/02538af80b7e819abe8a2260b0172ec2
Sales Agreement
Purple Biotech Ltd. (the “Registrant” or the “Company”) is announcing that on June 9, 2021, the Company entered into an Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC (the “Agent”) to issue and sell the Company’s American Depositary Shares, each representing 10 ordinary shares of the Company no par value (the “ADSs”), with gross sales proceeds of up to $50.0 million, from time to time, through an at the market offering through the Agent.
Subject to the terms and conditions of the Sale Agreement, the Agent has agreed to use its commercially reasonable efforts, consistent with its normal sales and trading practices to place the ADSs with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in a written notice from the Company. The sales, if, under the Sale Agreement will be made (i) in negotiated transactions with the consent of the Company or (ii) by any other method permitted by law deemed to be an “at the market” offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”), including block transactions, sales made directly on The Nasdaq Capital Market or any other existing trading market of the ADSs. The Sale Agreement provides that the commission payable to the Agent for sales of ADSs with respect to which the Agent acts as sales agent shall be up to 4.0% of the gross proceeds of ADSs sold pursuant to the Sale Agreement.
The Sale Agreement contains customary representations and warranties of the parties to each other and indemnification and contribution provisions under which the Company and the Agent have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. The Agent and the Company have the right, by giving written notice as specified in the Sale Agreement, to terminate the Sale Agreement.
The offering has been registered under the Securities Act pursuant to the Company’s shelf registration statement on Form F-3 (Registration No. 333-235327), as supplemented by the prospectus supplement dated June 9, 2021 relating to the sale of the ADSs.
A copy of the Sale Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Sale Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.
A copy of the opinion of ABZ Law Office of Jerusalem, Israel relating to the validity of the ordinary shares underlying the ADSs to be issued in accordance with the Sale Agreement is filed herewith as Exhibit 5.1. A copy of the opinion of Haynes and Boone LLP relating to the validity of the ADSs is filed herewith as Exhibit 5.2
This report on Form 6-K, and the above referenced registration statement and prospectus supplement, shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of ADSs or ordinary shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
------
Sales Agreement Form 424B5 - filed by Purple Biotech Ltd.
https://newsfilter.io/a/4c7ceea147b08ad5a05a2c2e0271623f
Purple Biotech Ltd.
Up to $50,000,000
American Depositary Shares representing Ordinary Shares
We have entered into an open market sale agreementSM (the “sales agreement”), with Jefferies LLC (“Jefferies” or the “Agent”), relating to the sale of American Depositary Shares (“ADSs”), representing our ordinary shares offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell ADSs having an aggregate offering price of up to $50,000,000 from time to time through Jefferies, acting as our agent.
The ADSs are listed on the Nasdaq Capital Market (“NASDAQ”) under the symbol “PPBT.” On June 8, 2021, the last reported sale price of the ADSs on NASDAQ was $5.20 per ADS. Our ordinary shares are also listed on the Tel Aviv Stock Exchange (“TASE”) under the symbol “PPBT.” On June 8, 2021, the last reported sale price of our ordinary shares on the TASE was NIS 16.46, or $5.10 per ordinary share (based on the exchange rate reported by the Bank of Israel on such date, which was NIS 3.243= $1.00).
Sales of the ADSs, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Jefferies is not required to sell any specific amount of securities but will act as a sales agent using commercially reasonable efforts to sell on our behalf all of the ADSs requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between the Jefferies and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The compensation to the Jefferies for sales of ADSs sold pursuant to the sales agreement will be an amount up to 4.0% of the gross proceeds of any ADSs sold under the sales agreement. In connection with the sale of the ADSs on our behalf, Jefferies will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act or under the Exchange Act of 1934, as amended (the “Exchange Act”). See “Plan of Distribution” on page S-25 of this prospectus supplement for additional information concerning the Jefferies’ compensation.
Investing in our securities involves a high degree of risk. Please read “Risk Factors” beginning on page S-6 of this prospectus supplement, on page 3 of the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.
---------------
financials Results (3-month)
https://fintel.io/doc/sec-purple-biotech-ltd-1614744-6k-2021…
----
Wird interessant jetzt.. Nun können Sie Aktien im Gegenwert von 50 Mio. USD ausgeben, wann immer sie es wollen und der Markt es zulässt. Da sie aktuell kein Cash benötigen, scheint es aus meiner Sicht eher so, dass diese Aktien strategisch benutzt werden, um zum Beispiel einen Partner mit ins Boot zu holen..
Ähnlich hat es zum Beispiel auch Trillium mit Pfizer gemacht...
Auf jeden Fall ist es nun interessant zu sehen, was passiert. NAchbörslich hat es jedenfalls KEINEN Abverkauf gegeben, der Markt hat es eher positiv aufgenommen...
Bei PPBT ist halt immer alles möglich, KEINE langweilige Aktie :-)
LG
Sven
Leute, momentan ein bull flag….. hier wird noch Einiges möglich sein 🤗🤗🍀🍀🍀
Trading Spotlight
So ein bischen verrückt ist das schon was hier passiert. Irgend jemand verdient hier richtig Kohle und irgend jemand wird die Zeche bezahlen müssen. Ich bin dezent froh, heute nicht ganz so entscheidungsfreudig zu sein. 🤣👌
Schöne Erholung bisher
https://www.cnbc.com/quotes/PPBT
https://www.cnbc.com/quotes/PPBT
Gleichzeitig ärgere ich mich, dass ich heute morgen nicht ein paar Gewinne realisiert habe, denn im Grunde war ja fast klar, dass es so kommen würde. Trotz des Ärgere habe ich eben meine Position um weitere 250 Stück aufgestockt. Purple ist jetzt mit 1.250 Stücken mein drittgrößter Depotwert.
Antwort auf Beitrag Nr.: 68.406.983 von schaunundstaunen am 04.06.21 15:21:57Da hast Du Recht, aber bei Biotechs braucht es manchmal viel Geduld. Die Studiendaten - und wir reden über Phase 1! - sind vielversprechend und es sieht mal wieder nach dem üblichen Sell on good news aus, mit dem die schwachen Hände rausgedrängt werden. Ich bin mir ziemlich sicher, dass institutionelle Investoren heute beherzt zugreifen und die Aktie wird zügig steigen. Das Handelsvolumen ist hoch genug.
was für eine kackaktie… jetzt reicht es mir.. verkauf… so lange gehalten und dann das, da gibt es zig tausend bessere aktien
Durchsuchen
